Please assess the completion status of the following clinical trial:

Trial Title: Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Taking prescribed opioid pain medications in an amount in excess of 30 Morphine Equivalent Dose (MED) for 6 months or longer.~* Have been recommended to wean or reduce their MED.~* Medically stable such that subject does not have unstable angina, COPD requiring supplemental oxygen, untreated or active cancer or similar conditions that would make participation difficult or unsafe.~* Compliant with all physician recommendations relating to medication usage.~* Ambulatory and able to use the toilet independently.~* Negative pregnancy test in subjects of childbearing potential~* Willing to attempt opioid pain medication taper.~* Competent to provide informed consent.~* Capable of understanding and completing study questionnaires.~* Subject willing to participate in the study for up to 12 weeks.~Exclusion Criteria:~* Not capable of understanding or completing study questionnaires.~* Lacking capacity to provide fully informed consent.~* Substance use disorder not in remission.~* Considering surgery or other invasive procedures that would take place during the study.~* Used isotretinoin (Accutane) within 6 months prior to study enrollment~* Cancer not in remission.~* Need of ongoing Transcutaneous Electrical Nerve Stimulation (TENS) therapy, massage therapy, chiropractic care or other treatments intended to remediate pain other than treatment in the Sharp Pain Program.~* A female who is pregnant or lactating, or of childbearing potential unless a medically acceptable method of birth control is in use.~* Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment.~* Used an investigational drug/device therapy or participated in any clinical investigation relating to pain within 4 weeks prior to study enrollment.~* A psychiatric or psychological condition that would place undo stress on the subject, prevent full participation or compromise data collection.~* The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ABAB (Type: OTHER): Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation.
- BABA (Type: OTHER): Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy